Baxter BioPharma Reaches Deal For Fill/Finish Manufacturing Of Moderna COVID-19 Vaccine In U.S.

百特生物制药公司达成在美国生产Moderna新冠疫苗填充/成品的交易。

2021-03-09 00:52:53 RTTNews

本文共265个字,阅读需1分钟

Baxter International Inc. and Moderna Inc. said that they have reached an agreement by which Baxter BioPharma Solutions to provide fill/finish sterile manufacturing services and supply packaging for about 60-90 million doses of the Moderna COVID-19 Vaccine in 2021. Additional details of the agreement were not disclosed. Baxter's BioPharma Solutions business is a premier contract manufacturing organization that specializes in parenteral (injectable) pharmaceuticals, including vaccines. The manufacturing of the Moderna COVID-19 vaccine will take place at the BioPharma Solutions fill/finish sterile manufacturing facilities located in Bloomington, Indiana. For comments and feedback contact: editorial@rttnews.com Business News
百特国际公司和Moderna公司表示,双方已达成协议,由百特生物制药解决方案公司为2021年约6000-9000万剂Moderna新冠疫苗提供填充/完成无菌制造服务,并提供包装。协议的其他细节没有透露。 百特公司的生物制药解决方案业务是一家主要的合同制造机构,专门从事肠外(注射)药物,包括疫苗。 Moderna COVID-19疫苗的生产将在位于印第安纳州布卢明顿的BioPharma Solutions Fill/Finish无菌生产设施进行。 如需评论和反馈,请联系:editorial@rttnews.com 商业新闻

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文